The Municipal Hospital of Cubatão in Brazil has initiated a new treatment protocol for premature infants at risk of Respiratory Syncytial Virus (RSV), a significant cause of bronchiolitis and pneumonia in children under one year. The treatment involves administering Nirsevimab, a long-acting monoclonal antibody designed specifically to provide immediate protection to these vulnerable infants. This marks a significant advancement in the hospital's capacity to prevent serious respiratory issues among newborns.

On February 13, the hospital marked a historic milestone by administering the first dose of Nirsevimab to a newborn, symbolizing a commitment to enhancing the health outcomes for premature babies facing potential complications from RSV. The municipal government's announcement underlined the importance of this treatment in safeguarding infants with pre-existing health conditions and those born prematurely, who are at greater risk of severe respiratory illnesses during their early life.

Unlike traditional vaccines, Nirsevimab provides ready-made antibodies that confer immediate and long-lasting protection, crucial during the RSV season when infections tend to rise sharply. The introduction of this treatment in Cubatão reflects a broader effort to improve pediatric care and reduce hospitalizations linked to respiratory illnesses among Brazilian infants.